NCT06571448View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions
Trigeminal Neuralgia
Interventions
DRUG

SR750 tablet

SR750 high dose BID orally for 6 weeks

DRUG

SR750 tablet

SR750 low dose BID orally for 6 weeks

DRUG

Placebo

Placebo

All Listed Sponsors
lead

Shanghai SIMR Biotechnology Co., Ltd.

INDUSTRY

NCT06571448 - Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia | Biotech Hunter | Biotech Hunter